Filing identity and period
Important discrepancy: The request identifies Skye Bioscience, Inc., but the supplied Form 10-Q is for Load Guard Logistics, Inc. It reports the three months ended January 31, 2014, the company’s fiscal first quarter. The interim financial statements are unaudited. This summary reflects the supplied filing, not Skye Bioscience.
Load Guard describes itself as a development-stage transportation and delivery services company, earning revenue from freight transportation and brokerage services.
Financial performance
| Metric | Three months ended Jan. 31, 2014 | Three months ended Jan. 31, 2013 |
|---|---|---|
| Operating revenue | $63,421 | $57,130 |
| Operating expenses | $64,651 | $63,324 |
| Operating loss | $(1,230) | $(6,194) |
| Gain on insurance claim | $4,853 | $6,506 |
| Net income | $3,620 | $160 |
| Cash used in operating activities | $(4,145) | $(12,489) |
- Revenue rose approximately 11%. The 2014 quarter included $47,554 of direct trucking revenue and $15,867 of brokerage income.
- Operating margin improved to approximately negative 1.9% from negative 10.8%; net margin was approximately 5.7% versus 0.3%. Net income included a $4,853 insurance-claim gain, while the operating business remained loss-making.
- Operating expenses increased approximately 2%. Fuel expense fell to $20,524 from $24,581, and professional fees fell to $2,975 from $7,537; operations and maintenance and general and administrative expenses increased.
- Basic and diluted earnings per share were reported as $0.00 in both periods. Weighted-average shares increased to 3,623,500 from 2,963,505.
Liquidity, debt, and cash flow
- At January 31, 2014, cash was $46,476, current assets were $103,650, and current liabilities were $53,839. Working capital was $49,811, up from $43,817 at October 31, 2013.
- Total liabilities were $53,839, consisting of current liabilities. Related-party notes payable totaled $41,048, all classified as current; the notes were due in March and June 2014. The filing reports $410 of interest expense for the quarter.
- Cash declined by $5,710 during the quarter. Operating activities used $4,145; investing activities used no cash; financing activities used $1,565, including $6,190 of loan repayments partly offset by $4,625 received on notes receivable.
- Accounts receivable was $34,802, including approximately $15,900 attributable to one customer. Notes receivable were $8,394 and due within one year.
Outlook, risks, and other material matters
- The going-concern note says the operating loss and negative operating cash flow raise substantial doubt about the company’s ability to continue as a going concern. Management planned to seek public or private equity financing and loans from officers and directors; it cautioned that funding plans might be insufficient and were not assured.
- Elsewhere, management stated it expected current cash and operating income to cover the next twelve months. This assessment differs from the substantial-doubt disclosure in the notes.
- Management said fuel costs were high relative to trucking revenue because of low revenue per mile under competitive freight-broker tenders. It expected professional fees to increase with continuing SEC reporting requirements.
- One customer represented approximately 47.4% of quarterly revenue and 45.6% of receivables, creating customer concentration risk.
- Related-party financing and other support are important to the business. Management disclosed no written commitment for officers or directors to provide additional funding, and noted potential conflicts of interest.
- Management reported ineffective disclosure controls and identified material weaknesses, including no functioning audit committee, insufficient independent board oversight, inadequate segregation of duties, and management concentration in one individual.
- The filing reported no material legal proceedings, commitments or contingencies, or material off-balance-sheet arrangements.
Key facts for investors to verify
- Confirm the issuer: the supplied filing is for Load Guard Logistics, Inc., not Skye Bioscience, Inc.
- Reconcile management’s twelve-month liquidity statement with the note’s substantial-doubt going-concern conclusion and determine whether financing was obtained.
- Review the insurance-claim gain’s nature, recurrence, and cash impact; reported net income exceeded operating performance.
- Assess repayment or refinancing of the related-party notes due in 2014 and the extent of any continuing insider support.
- Evaluate customer concentration, receivable collections, and remediation of the disclosed internal-control material weaknesses.